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Abstract 
Purpose:  Paracetamol has been associated with a reduction in blood pressure, especially in 
febrile, critically-ill adults. We hypothesised that blood pressure would fall following 
administration of paracetamol in critically-ill children and this effect would be greater during 
fever and among children with a high body surface area to weight ratio. 
 Methods: A 12-month prospective observational study of children (0-16 years) admitted to 
paediatric intensive care, who underwent pulse contour analysis and received paracetamol 
concurrently. 
Results:  Mean arterial blood pressure decreased significantly by 4.7% from baseline (95% CI 
1.75-8.07%) in 31 children following 148 doses of paracetamol. The nadir was 2-hours post-
dose. The effect was pronounced in children with fever at baseline (6.4%, 95% CI 2.8-10%), 
although this was not statistically significant. There was no simple relationship between this 
effect and body surface area to weight ratio. The association between a change in blood 
pressure and changes in heart rate or measured stroke volume was poor; therefore it was 
likely that a change in the systemic vascular resistance contributes most to this effect. 
Conclusion: There is a significant but modest reduction in blood pressure post-paracetamol 
in critically-ill children. This is likely related to a change in systemic vascular resistance. 
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Introduction: 
Paracetamol is associated with a reduction in blood pressure in critically-ill adults1-5. The 
reported decrease ranges between 7 and 15% from baseline and occurs over the first 2 
hours. The haemodynamic mechanism for this blood pressure decrease has been explored 
using various methods. Some authors have reported a reduction in cardiac output - either 
due to a reduction in heart rate6, or due to the diuretic effect of mannitol present in 
intravenous paracetamol preparations7.  However, there is also evidence to suggest that the 
reduction in blood pressure is related to a decrease in the systemic vascular resistance 
(SVR): (a) peripheral blood flow increases when measured using laser Doppler flowmetry in 
febrile patients8; and (b) a reduction in SVR has been observed following paracetamol 
administration when measured in a randomised controlled trial of healthy volunteers, but 
not after an equivalent dose of mannitol alone was given7. 
Although the use of paracetamol has been associated with a modest reduction in mean 
blood pressure in neonates9, the haemodynamic effects have not been evaluated in 
critically-ill children. If the phenomenon is based on a reduction in SVR, this effect may be 
greater in children, because they have a larger body surface area to weight (BSA-to-weight) 
ratio than adults.   
The hypotensive effect of paracetamol has been most studied during fever1 2 8. Fever is an 
increase in the hypothalamic temperature ‘set-point’ following pathogen invasion or tissue 
damage. The hyperthermia of fever is produced by an increase in metabolic rate, and a 
reduction in surface heat loss, through peripheral vasoconstriction. Paracetamol resets this 
central ‘set-point’: this opposes heat-conserving vasoconstriction, explaining a fall in both 
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SVR and blood pressure. However the haemodynamic impact of paracetamol may be 
complex given that heart rate also increases with temperature10.  
 
We hypothesise that (a) critically-ill children will show a significant reduction in blood 
pressure following paracetamol administration with a reduction in SVR, and (b) this effect 
will be greatest in children with fever, and those with higher BSA-to-weight ratio. 
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Methods: 
We conducted a prospective observational study of children admitted to our paediatric 
intensive care unit between October 2014 and October 2015, who (a) underwent cardiac 
output monitoring via pulse contour analysis (Lidco Rapid, LiDCO Ltd, U.K.) and (b) received 
one or more dose of paracetamol by any route.  
The decision to use cardiac output monitoring was made by the treating clinical team. Mean 
arterial blood pressure (MABP), heart rate (HR) and stroke volume index (SVI) data were 
recorded every 3-8 seconds by the cardiac output monitor (variable frequency as data 
automatically compressed for longer recordings). Data points with an inferior signal (as 
identified by the monitor - for example when the arterial line was being sampled) were 
excluded. The pulse contour measurements were calibrated using non-invasive (supra-
sternal) continuous wave Doppler ultrasound (USCOM Ltd, Australia) at the start of 
recording, and every 24 hours.  
Haemodynamic data from the hour before paracetamol was given, the hour paracetamol 
was given and four hours post-paracetamol administration, were compared. As a summary 
measure, we used the mean of 200 consecutive values of MABP, HR and SVI centred around 
the hour mark i.e. if data were recorded every 3 seconds, mean values between 5 minutes 
before (3 seconds x 100 readings) and 5 minutes after the hour were used. In addition, we 
collected data on the following confounders from the electronic health record: vasoactive 
drug doses; fluid administered as a bolus of >=5ml/kg; sedation changes, furosemide, mean 
airway pressure changes (all expressed as increase, decrease or no change) and 
physiotherapy (expressed as a binary variable).  
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The data were analysed using multi-level linear regression modelling, with (a) either MABP, 
HR or SVI as outcome variables; (b) time, expressed as hours from the paracetamol dose (i.e. 
-1, 0, 1, 2, 3, 4), along with the above confounders as fixed effect variables, and (c) each 
dose administration and patient as random effect variables. This enabled us to evaluate 
changes in MABP, HR and SVI in relation to the time from the paracetamol dose, evaluating 
the effect per dose, per patient. This controlled for the assumption that each patient may 
not have the same haemodynamic effect with paracetamol as another, and the effect may 
vary between doses in the same patient. Each patient therefore was their own control, with 
a comparison made before and after paracetamol. 
Change in MABP is either due to HR, SV or SVR (pressure = flow x resistance). Although SVR 
is calculated by the Lidco Rapid pulse contour analyser, a static central venous pressure is 
assumed. We do not routinely measure or target central venous pressure in our intensive 
care unit, especially as femoral venous liens are used preferentially to internal jugular or 
subclavian venous lines. Therefore we used linear regression to examine the effect of HR 
and SVI on MABP: from the coefficient of determination (adjusted R2, the proportion of 
change in MABP explained by the changes in HR and SVI) we inferred the relative effect of 
SVR on MABP (i.e. 1-R2). 
To test our two a priori hypotheses we added temperature to our model, and analysed 
children separately according to whether they had a fever (defined as a temperature >38oC) 
at baseline. We similarly analysed children separately according to BSA-to-weight ratio 
quartiles, and those with and without fever at baseline (axillary/oesophageal 
temperature>=38oC at time-points -1 or 0) using a time-point interaction term for both in 
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the multi-level regression models. Analyses were carried out using Microsoft Excel 
(Microsoft Corp, WA, USA) and r (ww.cran.r-project.org).  
Data were collected as a part of a locally registered service evaluation. Informed consent 
was not required as only non-identifiable, routinely collected clinical data were used. 
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Results: 
Thirty-one children received 148 paracetamol doses during cardiac output monitoring. 
Median age was 37 months (IQR 18-109 months). One hundred and twenty seven (85%) 
doses were intravenous (Table 1). Doses ranged from 10-15mg/kg. MABP decreased post-
paracetamol, with the nadir at two hours (2 hours post intravenous dose; 3 hours post 
enteral dose). The mean reduction in blood pressure was small – from 68 to 65 mm Hg; the 
median reduction was from 67 mm Hg to 64 mm Hg. However the top quartile decrease 
ranged from 9 mm Hg to 32 mm Hg, a percentage change between 12.5 to 34.8% from 
baseline. The effect was mostly consistent following intravenous paracetamol, with a more 
variable change in blood pressure following enteral paracetamol (although the number of 
enteral doses was relatively small).  Systolic blood pressure followed a similar pattern, 
although diastolic blood pressure was largely unchanged during the time period. (Figure 1) 
Following multi-level regression analysis, MABP decreased significantly two hours post-
paracetamol by a mean of 4.7% (95% CI 1.8-8.1%; p<0.05) i.e. 3.3 mmHg decrease from a 
mean baseline of 68 mmHg. This decrease was largely secondary to a reduction in systolic 
blood pressure, which decreases by a mean of 6.9% (95% CI 3.6-10.9%; p<0.05) i.e. 7 mmHg 
decrease from a mean baseline systolic of 101 mmHg. Diastolic blood pressure did not 
change significantly.  HR and SVI both decreased, reaching statistical significance on multi-
variable analysis (Table 2). 
Mechanistic explanation of blood pressure changes: To understand the relative 
contributions of HR, SV and SVR on the effect of blood pressure, we used a linear regression 
model, with change in MABP from baseline at two hours as the outcome, and the change in 
HR and SV over the same period as predictors. A change in SVI significantly predicted a 
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change in MABP.  The adjusted R2 value from this model, which evaluates the proportion of 
the change in MABP explained by the changes in HR and SVI, was only 5%. By inference 
therefore, most (i.e. approximately 95%) of the change is blood pressure is related to a 
change in vascular resistance. When the derived SVRI from the cardiac output monitor (with 
static central venous pressure) was used in the model, (i.e. change in MABP at 2 hours as 
the outcome and change in HR, SV and SVR as predictors) the R2 value was 0.84. 
Effect of fever on reduction in blood pressure: We analysed the pre-specified subgroup of 
children with fever. Fifty-four children had a fever (>38oC) at baseline. To analyse the effect 
of fever we included temperature separately into the multi-level regression model, and 
analysed the subgroup of doses where children were febrile at baseline (temperature 
>38oC). Fifty four doses (36%) of paracetamol were given when the children had a fever. 
Temperature did not have an independent effect on mean blood pressure. With temperature 
included in the model, the reduction in mean blood pressure at two hours  was 5.6% ( 95% CI 1.7-
21.6%) – while the mean difference is similar, the confidence intervals are wider given the number 
of missing data points as temperature is not always measured continuously or hourly. Following 
multi-variable analysis of the sub-group with fever, the reduction in blood pressure was 
4.4% of baseline at two hours (95% CI 1.5-12.3%), which remained statistically significant 
(p<0.05).  
Effect of body surface area to weight ratio on reduction in blood pressure: When analysed 
for each quartile of BSA-to-weight ratio, MABP dropped with the lower three BSA-to-weight 
ratio quartiles post-paracetamol, but not the top quartile, where paradoxically there was no 
significant change in blood pressure [MABP decrease quartile 1: 5.3% (95% CI 0.9, 10.4%); 
quartile 2: 4.5% (95% CI 0.3, 10.0%); quartile 3: 6.2% (95% CI 2.1, 11.3%);  quartile 4: 1.0% 
 10 
(95% CI -3.4, 7.1%)]. When tested using BSA-to-weight ratio as an interaction term (as 
above), there was no significant difference in the effect of paracetamol on MABP between 
the quartiles (p>0.05). 
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Discussion: 
Critically-ill children show a significant reduction in their mean blood pressure, with the 
greatest fall observed 2 hours post-paracetamol administration. This fall is poorly explained 
by stroke volume and heart rate changes alone, implying a likely role of a change in SVR as 
the main effector of the fall in blood pressure. This effect is seen in children with and 
without fever, although paradoxically not in children with the highest BSA-to-weight ratio in 
our cohort. 
While the change in blood pressure is statistically significant, we do acknowledge the overall 
effect is small: a 4.7% reduction from a mean baseline of 68 mmHg amounts to a drop in 
blood pressure of just over 3 mmHg. The change in systolic blood pressure is expectedly 
greater, with a near 7% reduction i.e. a reduction from a mean baseline of 101 mmHg to 94 
mmHg. One can question the clinical significance of this. However we noted that for 33/148 
doses of paracetamol, a fluid bolus was given within the following 4 hours. Similarly in 7/148 
doses, the dose of norepinephrine was increased. This is likely to be a reaction to a change 
in haemodynamics: either the reduction in blood pressure or the bedside cardiac output 
data on display (we have not tested the effect of having a persistent display of 
haemodynamic parameters by the bedside on the number of interventions or outcome). 
The time-course of blood pressure changes in our cohort are more prolonged than 
previously described. Most studies report changes over the first 2 hours only and therefore 
cannot be directly compared. However in our cohort the nadir of the blood pressure 
reduction was at 2 hours (and 3 hours if enteral paracetamol was used). Blood pressure 
does return to baseline by 4 hours post dose. This may be an effect unique to critically-ill 
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children and needs further exploration. We did not explore any dose related interactions, 
nor did we correlate the effect to serum levels of paracetamol. 
The observed blood pressure effect of paracetamol is likely due to a reduction in vascular 
resistance, as has been reported in previous adult studies7, 8. This is consistent with the 
hypothesis that paracetamol may release the vasoconstriction induced by fever. However 
although the blood pressure reduction was greater in children with fever, statistically we 
were unable demonstrate this difference to be significant. Regardless, the effect may still be 
the same if paracetamol was used for analgesia: the analgesic effect of paracetamol may be 
releasing stress induced vasoconstriction. Paracetamol reduces both HR and SV, as well as 
SVR. The reduction in cardiac index associated with paracetamol has been described 
previously6. The mechanism behind this is unknown: Chiam et al hypothesised that this 
reduction may be due to SV changes secondary to mannitol used as a stabilizer in most 
intravenous paracetamol formulations. However in a randomised controlled trial of healthy 
volunteers, Chiam et al did not observe this effect: cardiac index increased in their 
experiment with both paracetamol and a dose equivalent mannitol infusion7. However the 
time course of blood pressure change we describe in our patients is different. The 
haemodynamic effects may also vary between healthy volunteers and in critical illness – 
paracetamol may have a mild negative inotropic effect, which can only be observed in 
haemodynamically compromised patients. It is also likely that the variables are not mutually 
independent e.g. HR reduction may improve cardiac output and blood pressure in the 
context of diastolic dysfunction. Therefore the effect of each variable may be unique to each 
individual’s haemodynamic state at any given time. 
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Our data do not support the hypothesis that children a higher BSA-to-weight ratio will have 
a greater drop in blood pressure due to peripheral vasodilation. This may be due to a lack of 
power with sub-group analysis. However our hypothesis was based on peripheral 
vasodilation being the dominant mechanism. Given our findings that blood pressure 
changes are seen even in those without fever, central vasodilation, potentially from the 
analgesic effect of paracetamol, may explain the fall in MABP. This needs further 
exploration. 
Our study has some limitations. Although the number of paracetamol doses studied is large, 
the number of patients is small. Nevertheless the sample size is comparable to similar 
studies in adults. We do not have control subjects in whom paracetamol was not used. We 
have not accounted for the dose or serum levels of paracetamol: most doses were intended 
as 15mg/kg, although weights were often estimated in unplanned admissions.  We used the 
Lidco Rapid pulse contour analyser. Pulse contour analysis offers the advantage of 
producing a continuous measure, with bedside display and data capture. However pulse 
contour analysis is not well validated for use in children. In our analysis, trends were more 
important than the absolute values – each patient was their own control. The 
measurements were calibrated using suprasternal Doppler measurements. Although 
suprasternal Doppler measurements of haemodynamic variables has its own drawbacks 
(inter and intra-user variability), this is increasingly more widely accepted as a monitoring 
technique11. There are also concerns regarding calibration drift with pulse contour analysis: 
this has been reported as occurring over 2-4 hours12. Although not systematically tested, 
when suprasternal Doppler measurements were taken every 4 hours, the agreement with 
pulse contour measurements remained relatively stable in our population, even up to 24 
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hours. We would recommend a prospective study with using an alternative cardiac output 
measurement technique to verify our findings. Despite this, the blood pressure changes 
were directly observed from the arterial catheter, and therefore are not subject to the 
limitations of the cardiac output monitor. 
 
Our observation that blood pressure decreases following paracetamol administration in 
critically-ill children is consistent with findings in adults. Although the effect size on blood 
pressure is modest, given the proportion of interventions following each dose of 
paracetamol, this needs careful consideration in critically children. The recent HEAT trial did 
not show any harm or benefit of paracetamol when compared to placebo13. In children with 
shock, a change in systemic haemodynamics, or the compensatory treatment, may alter the 
balance between physiological cost and benefit of paracetamol treatment.    
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Patient 
number 
Weight 
(kg) 
Body 
Surface 
Area 
(m
2
) 
Fever 
(baseline 
temperature
>=38
o
C) 
Age 
(months) 
Diagnosis 
Intra-venous 
doses  of 
paracetamol 
Total 
paracetamol 
doses 
1 13.3 0.58 Yes 38 RSV bronchiolitis 6 11 
2 10.5 0.48 No 26 Pneumonia 1 1 
3 11.4 0.48 No 26 CMV pneumonitis 4 4 
        
4 18 0.74 Yes 64 
Septic shock, acute 
appendicitis 7 7 
        
5 4 0.24 No 1 Bronchiolitis 0 2 
        
6 15 0.64 Yes 49 
Streptococcal 
pneumonia 9 9 
        
7 28.5 1.05 Yes 123 
Staphylococcal 
pneumonia 4 4 
        
8 8 0.36 No 6 Bronchiolitis 0 3 
9 8.8 0.41 Yes 15 Pneumonia 2 2 
10 65 1.71 No 156 Status asthmaticus 3 3 
11 9 0.33 Yes 35 Septic shock 10 10 
        
12 28 0.97 Yes 89 
Post cardiac arrest, 
primary cardiac 
arrhythmia 0 1 
        
13 8.5 0.31 No 8 Pneumonia 5 5 
14 10 0.47 No 14 Empyema 1 5 
15 29.3 0.88 No 41 Influenza pneumonitis 0 1 
        
16 3.6 0.22 No 1 
Group B Streptococcal 
sepsis 0 3 
17 12 0.54 Yes 30 Toxic shock syndrome 3 3 
18 65 1.69 Yes 167 ARDS 11 11 
19 14 0.57 Yes 37 Aspiration pneumonia 2 2 
        
20 11.2 0.48 No 31 
Influenza 
pneumonitis, aplastic 
anaemia 11 11 
        
21 60 1.6 No 141 Renal cell carcinoma 6 6 
22 11.11 0.52 No 22 Propionic acidaemia 3 3 
        
23 8.1 0.35 Yes 18 
Metapneumovirus 
bronchiolitis 0 2 
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24 56 1.71 No 180 Subdural empyema 2 2 
25 72 1.86 Yes 181 Crohn's disease 3 3 
        
26 45 1.27 Yes 147 Post cardiac arrest 1 1 
        
27 22 0.83 Yes 95 
Staphylococcal 
pneumonia 2 2 
        
28 10 0.49 No 23 Neutropenic sepsis 9 9 
        
29 17 0.76 Yes 75 
Haemophagocytic 
lymphohistiocytosis 10 10 
        
30 5.3 0.26 Yes 2 
Sepsis, congenital 
hyperinsulinism 1 1 
        
31 58 1.57 No 114 Septic shock 11 11 
Table 1: Characteristics of children with cardiac output monitoring given doses of paracetamol. Weight was either 
measured or estimated. Body surface area was calculated using weight and height data (as calculated by the Lidco 
Rapid pulse contour analyser).  
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Time-points  
(hours after 
paracetamol 
dose) 
Mean 
arterial 
blood 
pressure, 
mm Hg (95% 
CI) 
% change 
from 
baseline 
(95% CI) 
Heart rate, 
beats per 
minute (95% 
CI) 
% change 
from 
baseline 
(95% CI) 
Stroke 
volume 
index, 
ml/m2 (95% 
CI) 
% change 
from 
baseline 
(95% CI) 
-1 
68.3  
(63.5, 73.2)  
130.1  
(121.8, 138.4)  
32.6  
(27.4, 37.7)  
       
 
0 
67.5  
(61.2, 73.8) 
-1.2  
(-3.6, 0.9) 
131.4  
(121.0, 141.8) 
1.0  
(-0.7, 2.5) 
32.7  
(26.6, 38.8) 
0.4  
(-2.8, 2.7) 
       
1 
66.1  
(59.8, 72.4) 
-3.3  
(-5.9, -1.1) 
129.6  
(119.2, 140.1) 
-0.4  
(-2.1, 1.2) 
32.1  
(26.0, 38.1) 
-1.6  
(-5.2, 1.0) 
       
2 
65.1  
(58.8, 71.4) 
-4.8  
(-7.5, -2.5) 
126.8  
(116.4, 137.3) 
-2.5  
(-4.4, -0.8) 
31.4  
(25.3, 37.4) 
-3.7  
(-7.6, -0.8) 
       
3 
65.8  
(59.5, 72.1) 
-3.7  
(-6.3, -1.4) 
126.2  
(115.7, 136.6) 
-3.0  
(-5.0, -1.3) 
31.6  
(25.5, 37.7) 
-3.0  
(-6.9, -0.2) 
       
4 
66.7  
(60.4, 73.1) 
-2.3  
(-4.9, -0.1) 
127.5  
(117.0, 138.0) 
-2.0  
(-3.9, -0.3) 
32.7  
(26.6, 38.7) 
0.3  
(-3.0, 2.7) 
Table 2: Changes in mean arterial blood pressure, heart rate and stroke volume index with paracetamol. 
Paracetamol is given at time-point 0. Mean  values  with 95% confidence intervals of mean arterial blood 
pressure, heart rate and stroke volume index are shown, after correcting for vaso-active drug doses, fluid 
boluses, furosemide, sedation, mean airway pressure changes and physiotherapy in a multi-level linear 
regression model. Percentage changes from baseline (time-point -1) with 95% confidence intervals are 
provided in the adjacent columns. Statistically significant values are shown in red. Blood pressure decreases 
post-paracetamol, with a nadir at time-point 2, without fully recovering back to baseline. Heart rate also 
decreases, with a nadir at 3 hours. Stroke volume index decreases with a nadir at 2 hours, but recovers back 
to baseline within 4 hours. 
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 Figure 1: Bean plot showing distribution of mean, systolic and diastolic arterial blood pressure 
following 148 paracetamol doses in 31 patients. Paracetamol is given at time 0. There is a fall in 
mean and systolic arterial blood pressure, reaching a nadir 2 hours post-dose (4.7% and 6.9% of 
baseline respectively). This reduction in blood pressure is significant on multivariate analysis using a 
multi-level regression model (95% confidence interval 1.8-8.1% for mean and 3.6-10.9% for systolic 
blood pressure). The diastolic blood pressure however is relatively unchanged. 
 
